# Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

> **NCT03891862** · PHASE4 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 135 (actual)

## Conditions studied

- Tardive Dyskinesia (TD)

## Interventions

- **DRUG:** Valbenazine
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03891862
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2019-12-23
- **Final completion:** 2020-01-30
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03891862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03891862, "Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03891862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*